Skip to Content

Conivaptan Pregnancy and Breastfeeding Warnings

Conivaptan is also known as: Vaprisol

Conivaptan Pregnancy Warnings

Animal studies have revealed evidence of decreased neonatal viability and weaning indices, decreased body weight, and delayed reflex and physical development (including sexual maturation) when this drug was administered at a dose of 2.5 mg/kg/day. Fetal accumulation and delays in delivery may also be possible. No fetal or maternal adverse effects were observed when administered IV up to 12 mg/kg/day. There are no controlled data in human pregnancy. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

The manufacturer makes no recommendation regarding use during pregnancy. US FDA pregnancy category: Not assigned. Risk summary: No data available on use of this drug in pregnant women to inform a drug-related risk. Comments: May impair female fertility; unknown whether these effects are reversible.

See references

Conivaptan Breastfeeding Warnings

Use should be avoided. Excreted into human milk: Data not available Excreted into animal milk: Yes Comments: -Due to the potential for serious adverse events, including electrolyte abnormalities (e.g., hypernatremia), hypotension, and volume depletion in nursing infants, women should not breastfeed during treatment with this drug.

Milk levels in rats reached maximal levels 1 hour following IV administration of this drug and were up to 3 times the maternal plasma levels following an IV dose of 1 mg/kg (systemic exposure less than human therapeutic exposure based on AUC comparison).

See references

References for pregnancy information

  1. "Product Information. Vaprisol (conivaptan)." Cumberland Pharmaceuticals Inc, Nashville, TN.

References for breastfeeding information

  1. "Product Information. Vaprisol (conivaptan)." Cumberland Pharmaceuticals Inc, Nashville, TN.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.